HUTCHMED (China) Limited (LON:HCM – Get Free Report)’s share price crossed below its 200-day moving average during trading on Friday . The stock has a 200-day moving average of GBX 289.99 ($3.65) and traded as low as GBX 261 ($3.29). HUTCHMED shares last traded at GBX 264 ($3.33), with a volume of 39,973 shares traded.
HUTCHMED Stock Performance
The business has a 50 day moving average of GBX 284.72 and a 200-day moving average of GBX 289.99. The company has a debt-to-equity ratio of 11.78, a quick ratio of 2.97 and a current ratio of 2.81. The company has a market capitalization of £2.26 billion, a P/E ratio of -6,600.00 and a beta of 0.76.
HUTCHMED Company Profile
HUTCHMED (China) Limited, together with its subsidiaries, discovers, develops, and commercializes targeted therapeutics and immunotherapies for cancer and immunological diseases in Hong Kong and internationally. The company develops Savolitinib for the treatment of non-small cell lung cancer (NSCLC), papillary renal cell carcinoma (RCC), and gastric cancer (GC); and Fruquintinib, an inhibitor for colorectal cancer (CRC), breast cancer, gastric cancer, microsatellite stable-CRC endometrial cancer (EMC), NSCLC, RCC, gastrointestinal, cervical, and solid tumors.
Featured Articles
- Five stocks we like better than HUTCHMED
- Special Purpose Acquisition Company (SPAC) What You Need to Know
- How Whitestone REIT Is Transforming Sun Belt Retail Growth
- Business Services Stocks Investing
- Top-Performing Non-Leveraged ETFs This Year
- Stock Splits, Do They Really Impact Investors?
- Rivian’s Wild Ride: Is the Dip a Buying Opportunity?
Receive News & Ratings for HUTCHMED Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for HUTCHMED and related companies with MarketBeat.com's FREE daily email newsletter.